A61K 40/4242
Transcription factors
Official title: {Transcription factors, e.g. SOX or c-MYC}
A61K40/4242 (Transcription factors) appears on 182 US grants and 364 published applications in this corpus.
Search patents in A61K- Granted patents
- 182
- Published applications
- 364
- Assignees
- 180
- Inventors
- 620
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 8 |
| 2004 | 0 | 4 |
| 2005 | 0 | 3 |
| 2006 | 3 | 2 |
| 2007 | 0 | 2 |
| 2008 | 4 | 6 |
| 2009 | 5 | 3 |
| 2010 | 4 | 12 |
| 2011 | 5 | 9 |
| 2012 | 1 | 5 |
| 2013 | 6 | 3 |
| 2014 | 4 | 13 |
| 2015 | 9 | 11 |
| 2016 | 8 | 14 |
| 2017 | 7 | 13 |
| 2018 | 10 | 20 |
| 2019 | 10 | 31 |
| 2020 | 9 | 26 |
| 2021 | 16 | 28 |
| 2022 | 17 | 41 |
| 2023 | 14 | 34 |
| 2024 | 10 | 28 |
| 2025 | 22 | 27 |
| 2026 | 16 | 21 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Chimeric antigen receptors to HER2 and methods of use thereof22 Sep 2026US 12,742,020 B2BioAtla, Inc.
- Fixed ratio ex vivo activated mixed lymphocyte products for use in the treatment of cancer22 Sep 2026US 12,742,153 B2Children's National Medical Center
- Chimeric antigen receptor T cells and methods of use thereof30 Jun 2026US 12,668,777 B2Augusta University Research Institute, Inc.
- Nant cancer vaccine16 Jun 2026US 12,653,874 B2ImmunityBio, Inc.
- T-cell immunotherapy specific for WT-116 Jun 2026US 12,653,886 B2Fred Hutchinson Cancer Center
- Chimeric antigen receptor t cells and methods of use thereof8 Oct 2026US 2026/0308521 A1Augusta University Research Institute, Inc.
- A t cell receptor recognizing an unmutated foxm1 epitope presented on hla-a*02:011 Oct 2026US 2026/0297157 A1Board of Regents, The University of Texas System
- T cell receptors targeting tp53 hotspot mutations and uses thereof13 Aug 2026US 2026/0232801 A1Memorial Hospital for Cancer and Allied Diseases
- Compositions including anti-wt-1 antibodies & antigen binding fragments and uses thereof6 Aug 2026US 2026/0226173 A1
- Affinity and functional based screening of t cell receptor repertoire using three-dimensional shaped particles30 Jul 2026US 2026/0218282 A1The Regents of the University of California
Most cited
By later US patents
- Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases143US 8,956,828 B2Ospedale San Raffaele S.R.L. · 2015
- Tumor antigen based on products of the tumor suppressor gene WT145US 7,030,212 B1Haruo Sugiyama · 2006
- Stat3 antagonists and their use as vaccines against cancer41US 7,638,122 B2The Johns Hopkins University · 2009
- Targeted disruption of T cell receptor genes using talens38US 9,937,207 B2Ospedale San Raffaele S.R.L. · 2018
- Tumor antigen based on products of the tumor suppressor gene WT132US 7,608,685 B1International Institute of Cancer Immunology, Inc. · 2009